NCT02536911View on ClinicalTrials.gov

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Gaucher Disease

Interventions

DRUG

eliglustat

"Pharmaceutical form: capsule~Route of administration: oral"

Trial Locations (2)

33014

Investigational Site Number 840002, Miami

37920

Investigational Site Number 840001, Knoxville

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02536911 - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate | Biotech Hunter | Biotech Hunter